The serum level of microRNA-486-3p and its effects on proliferation and apoptosis of pancreatic cancer cells

doi:10.16138/j.1673-6087.2021.02.011

Abstract

Abstract:

Objective To investigate the serum level of microRNA-486-3p (miR-486-3p) and its effects on proliferation and apoptosis of pancreatic cancer cells. Methods Twenty-one patients with pancreatic cancer and twenty healthy controls were enrolled. Real-time polymerase chain reaction(PCR) was used to detect the serum miR-486-3p. The effects of miR-486-3p on pancreatic cancer cells proliferation and apoptosis were respectively examined by cell counting kit 8(CCK8) assay and flow cytometry assay. Results Compared with healthy controls,serum level of miR-486-3p was significantly up-regulated in patients with pancreatic cancer （50.73±0.82 vs 34.80±0.74, P<0.05）; The proliferation of pancreatic cancer cells were significantly up-regulated （SW1990: 2.77±0.07 vs 2.05±0.06, P<0.05; PANC-1: 2.81±0.04 vs1.89±0.04, P<0.05） and the apoptosis rates were suppressed by forced expression of miR-486-3p（24.1%±1.14% vs 45.9%±1.11%, P<0.05; 21.9%±0.25% vs 42.3%±1.62%, P<0.05）, while inhibition of miR-486-3p significantly down-regulated the proliferation of pancreatic cancer cells（SW1990: 1.71±0.03 vs 2.07±0.05, P<0.05; PANC-1: 1.61±0.03 vs 2.20±0.07, P<0.05）. Conclusions The serum miR-486-3p were significantly up-regulated in patients with pancreatic cancer; MiR-486-3p may function as a tumor-promoter by promoting cell proliferation and suppressing apoptosis in pancreatic cancer cells.

Key words: Pancreatic cancer, Serum microRNA-486-3p, Cell proliferation and apoptosis

CLC Number:

R735.9

LI Xiaoli, LI Weiguang, QIAN Aihua, CAO Guoliang. The serum level of microRNA-486-3p and its effects on proliferation and apoptosis of pancreatic cancer cells[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(02): 121-125.

Figures/Tables 2

References 31

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30. doi: 10.3322/caac.21387 URL
[2]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1), 7-30. doi: 10.3322/caac.21442 URL
[3]	Kuroczycki-Saniutycz S, Grzeszczuk A, Zwierz ZW, et al. Prevention of pancreatic cancer[J]. Contemp Oncol (Pozn), 2017, 21(1): 30-34.
[4]	Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma[J]. N Engl J Med, 2014, 371(11): 1039-1049. doi: 10.1056/NEJMra1404198 URL
[5]	Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer[J]. Nat Rev Cancer, 2018, 18(1): 5-18. doi: 10.1038/nrc.2017.99 pmid: 29170536
[6]	Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3): 203-222. doi: 10.1038/nrd.2016.246 pmid: 28209991
[7]	Li Z, Xu R, Li N. MicroRNAs from plants to animals, do they define a new messenger for communication[J]?. Nutr Metab, 2018, 15: 68. doi: 10.1186/s12986-018-0305-8 URL
[8]	Hayder H, O’Brien J, Nadeem U, et al. MicroRNAs: crucial regulators of placental development[J]. Reproduction, 2018, 155(6): 259-271. doi: 10.1530/REP-17-0603 pmid: 29615475
[9]	Chou ST, Peng HY, Mo KC, et al. MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1[J]. J Exp Clin Cancer Res, 2019, 38(1): 281. doi: 10.1186/s13046-019-1283-z URL
[10]	Ye HQ, Yu XL, Xia JY, et al. MiR-486-3p targeting ECM1 represses cell proliferation and metastasis in cervical cancer[J]. Biomed Pharmacother, 2016, 80: 109-114. doi: 10.1016/j.biopha.2016.02.019 URL
[11]	Li WG, Yuan YZ, Qiao MM, et al. High dose glargine alters the expression profiles of microRNAs in pancreatic cancer cells[J]. World J Gastroenterol, 2012, 18(21): 2630-2639. doi: 10.3748/wjg.v18.i21.2630 URL
[12]	Yu J, Li A, Hong SM, et al. MicroRNA alterations of pancreatic intraepithelial neoplasias[J]. Clin Cancer Res, 2012, 18(4): 981-992. doi: 10.1158/1078-0432.CCR-11-2347 URL
[13]	Fest J, Ruiter R, van Rooij FJ, et al. Underestimation of pancreatic cancer in the national cancer registry - reconsidering the incidence and survival rates[J]. Eur J Cancer, 2017, 72: 186-191. doi: S0959-8049(16)32604-1 pmid: 28033529
[14]	Bouvier AM, Bossard N, Colonna M, et al. Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study[J]. Eur J Cancer Prev, 2017, 26: S63-S69. doi: 10.1097/CEJ.0000000000000303 URL
[15]	Zhang S, Ng MK. Gene-microRNA network module ana-lysis for ovarian cancer[J]. BMC Syst Biol, 2016, 10 Suppl 4: 117.
[16]	Beheshti A, Vanderburg C, McDonald JT, et al. A circulating microRNA signature predicts age-based development of lymphoma[J]. PLoS One, 2017, 12(1): e0170521. doi: 10.1371/journal.pone.0170521 URL
[17]	Shigeyasu K, Toden S, Zumwalt TJ, et al. Emerging role of microRNAs as liquid biopsy biomarkers in gastrointestinal cancers[J]. Clin Cancer Res, 2017, 23(10): 2391-2399. doi: 10.1158/1078-0432.CCR-16-1676 URL
[18]	Youness RA, El-Tayebi HM, Assal RA, et al. MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc[J]. Oncol Lett, 2016, 12(4): 2567-2573. pmid: 27698829
[19]	Gu Y, Zhang X, Yang Q, et al. Aberrant placental villus expression of miR-486-3p and miR-3074-5p in recurrent miscarriage patients and uterine expression of these microRNAs during early pregnancy in mice[J]. Gynecol Obstet Invest, 2015. [Epub ahead of print].
[20]	Peng X, Wei F, Hu X. Long noncoding RNA DLGAP1-AS1 promotes cell proliferation in hepatocellular carcinoma via sequestering miR-486-5p[J]. J Cell Biochem, 2020, 121(2): 1953-1962. doi: 10.1002/jcb.29430 URL
[21]	Jin X, Pang W, Zhang Q, et al. MicroRNA-486-5p improves nonsmall-cell lung cancer chemotherapy sensitivity and inhibits epithelial-mesenchymal transition by targeting twinfilin actin binding protein 1[J]. J Int Med Res, 2019, 47(8): 3745-3756. doi: 10.1177/0300060519850739 URL
[22]	Yang S, Sui J, Liu T, et al. Expression of miR-486-5p and its signiﬁcance in lung squamous cell carcinoma[J]. J Cell Biochem, 2019, 120(8): 13912-13923. doi: 10.1002/jcb.28665 URL
[23]	Liu X, Chen X, Zeng K, et al. DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/β-catenin signal pathways[J]. Cell Death Dis, 2018, 9(10): 1037. doi: 10.1038/s41419-018-1105-9 URL
[24]	Chen H, Ren C, Han C, et al. Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma[J]. PLoS One, 2015, 10(3): e0119384. doi: 10.1371/journal.pone.0119384 URL
[25]	Balogh J, Victor D 3rd, Asham EH, Burroughs SG, et al. Hepatocellular carcinoma: a review[J]. J Hepatocell Carcinoma, 2016, 3: 41-53.
[26]	Li H, Mou Q, Li P, et al. MiR-486-5p inhibits IL-22-induced epithelial-mesenchymal transition of breast cancer cell by repressing Dock1[J]. J Cancer, 2019, 10(19): 4695-4706. doi: 10.7150/jca.30596 URL
[27]	Yang Y, Ji C, Guo S, et al. The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways[J]. Oncotarget, 2017, 8(42): 72835-72846. doi: 10.18632/oncotarget.20427 pmid: 29069829
[28]	Hummel R, Wang T, Watson DI, et al. Chemotherapy-induced modification of microRNA expression in esophageal cancer[J]. Oncol Rep, 2011, 26(4): 1011-1017.
[29]	Swierniak M, Wojcicka A, Czetwertynska M, et al. In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2013, 98(8): E1401-E1409. doi: 10.1210/jc.2013-1214 URL
[30]	Mosakhani N, Sarhadi VK, Borze I, et al. MicroRNA profiling differentiates colorectal cancer according to KRAS status[J]. Genes Chromosomes Cancer, 2012, 51(1): 1-9. doi: 10.1002/gcc.20925 URL
[31]	Huang YH, Lin KH, Chen HC, et al. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma[J]. PLOS One, 2012, 7(5): e37188. doi: 10.1371/journal.pone.0037188 URL

细胞	转染miR-486-3p 类似物		转染miR-486-3p 抑制剂
细胞	阴性对照	类似物	阴性对照	抑制剂
SW1990	2.05±0.06	2.77±0.07¹⁾	2.07±0.05	1.71±0.03¹⁾
PANC-1	1.89±0.04	2.81±0.04¹⁾	2.20±0.07	1.61±0.03¹⁾